Renal & hepatic impairment studies: the complexity behind the guidelines email

Renal & hepatic impairment studies: the complexity behind the guidelines

Dear Kenneth,

For many development teams, renal and hepatic impairment studies are planned late, resourced lightly, and treated as an operational formality. The assumption is that the guidelines are clear and the process is straightforward.

That assumption has a consistent set of consequences: stalled recruitment, late protocol amendments, and regulatory delays at the point of registration — when there is no longer time to course-correct.

What you’ll learn

● Why the first question any sponsor should answer is whether a dedicated RI/HI study is required at all — and the regulatory risk of getting this wrong
● The five study design gaps that surface most frequently during protocol discussions — from PK variability to control group matching
● What an integrated specialist ecosystem delivers in practice — and why standard early-phase units cannot replicate it
● Why early specialist engagement is not optional — it is the difference between a smooth programme and one that stalls at registration

Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.

By accessing this content, you are permitting Pharma Ignite or a third party to contact you regarding the content (by phone or email).